

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****National Institute of General Medical Sciences; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel; Review of Centers of Biomedical Research Excellence (COBRE) P20 Applications.

Date: June 27–28, 2019.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: The Doubletree Hotel, 8120 Wisconsin Avenue, Bethesda, MD 20814, 301–664–7305.

Contact Person: Manas Chattopadhyay, Ph.D., Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, Building 45, Room 3An12N, 45 Center Drive, Bethesda, MD 20892, 301–827–5320, manasc@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: April 30, 2019.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019–09097 Filed 5–2–19; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****National Cancer Institute; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel; Immunology Translation Network.

Date: June 13–14, 2019.

Time: 8:00 a.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Embassy Suites Baltimore Inner Harbor, 222 Saint Paul Place, Room Dorie, Baltimore, MD 21202.

Contact Person: Eun Ah Cho, Ph.D. Scientific Review Officer Research Programs Review Branch Division of Extramural Activities National Cancer Institute, NIH 9609 Medical Center Drive, Room 7W124 Bethesda, MD 20892–9750 240–276–6342 choe@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: April 30, 2019.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019–09098 Filed 5–2–19; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****Prospective Grant of Exclusive Patent License: Scopolamine Therapeutics for Depression and Bipolar Disorder**

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Institute of Mental Health (NIMH), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Repurposed Therapeutics, Inc. (“Repurposed Therapeutics”) located in Tampa, Florida, to practice the inventions embodied in the patent application listed in the Supplementary Information section of this notice.

DATES: Only written comments and/or applications for a license which are received by the NIMH Technology Transfer Office May 20, 2019 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated exclusive patent license should be directed to: Jennifer Wong, MS, Technology Development Coordinator, NIMH Technology Transfer Office, 35A Convent Drive, GE–400, Bethesda, MD 20892, phone number 301–480–4821, or wongje@mail.nih.gov.

SUPPLEMENTARY INFORMATION: The following patents/patent applications are the intellectual properties to be licensed under the prospective agreement to Repurposed Therapeutics: U.S. Patent 8,859,585, issued October 14, 2014, entitled “Scopolamine for the Treatment of Depression and Anxiety” [HHS Ref. No. E–175–2004–0–US–01]; Patent Cooperation Treaty (PCT) Application PCT/US2006/019335 filed May 18, 2006, entitled “Scopolamine for the Treatment of Depression and Anxiety” [HHS Ref. No. E–175–2004–0–PCT–02]; European Patent 1896025, issued December 28, 2011 entitled “Scopolamine for the Treatment of Depression and Anxiety” [HHS Ref. No. E–175–2004–0–EP–03]; Canadian Patent 2610025, issued July 22, 2014, entitled “Scopolamine for the Treatment of Depression and Anxiety” [HHS Ref. No. E–175–2004–0–CA–04]; German Patent 602006026717.7, issued December 28, 2011, entitled “Scopolamine for the Treatment of Depression and Anxiety” [HHS Ref. No. E–175–2004–0–DE–07]; French Patent 1896025, issued December 28, 2011, entitled “Scopolamine for the Treatment of Depression and Anxiety” [HHS Ref. No. E–175–2004–0–FR–08]; UK Patent 1896025, issued December 28, 2011, entitled “Scopolamine for the Treatment of Depression and Anxiety” [HHS Ref. No. E–175–2004–0–GB–09], and US Patent No. Patent 9,707,220, issued July 18, 2017, entitled “Scopolamine for the Treatment of Depression and Anxiety”